Chemed (CHE) Form 4: George Walsh Adds to Stake with $83K Purchase

Rhea-AI Filing Summary

Chemed Corp. (CHE) Form 4 filing: Director George J. Walsh III purchased 200 shares of Chemed common stock on 08/04/2025 at $417.10 per share, an outlay of roughly $83,420. His direct holdings rise to 3,523 shares; he also reports 434 shares held indirectly by his spouse. No shares were sold and no derivative positions were opened or closed. The transaction modestly increases the director’s exposure—about a 6% lift in his direct stake—while leaving total company share count essentially unaffected. Insider buying by a non-executive director is often interpreted as a vote of confidence, though the amount is immaterial compared to Chemed’s ~15 million shares outstanding.

Positive

• Director insider purchase indicates personal confidence in CHE’s prospects.
• Stake increased to 3,523 direct shares with no concurrent sales.

Negative

• Purchase volume is immaterial relative to Chemed’s total share count.
• Transaction size ($83 k) unlikely to impact market perception materially.

Insights

Equity Analyst

TL;DR: Modest insider buy; positive sentiment but financially immaterial.

Walsh’s $83 k purchase marginally enlarges his stake and signals confidence amid no concurrent sales. While such activity can boost investor sentiment, the purchased volume is negligible (<0.02% of shares outstanding) and unlikely to influence valuation. Nonetheless, repeated insider accumulation could become a bullish pattern worth tracking.

Corporate Governance Specialist

TL;DR: Clean Form 4; no red flags, small buy supports alignment.

The filing shows timely reporting, no derivative complexities, and straightforward direct ownership. Insider buying—particularly by an independent director—helps align board interests with shareholders and is governance-friendly. The size, however, is too small to materially alter incentive structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALSH GEORGE J III

(Last) (First) (Middle)

2600 CHEMED CENTER

255 EAST 5TH STREET

(Street)

CINCINNATI OH 45202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Capital Stock	08/04/2025		P		200	A	$417.1	3,523	D
Capital Stock								434	I	spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	George J. Walsh III	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Chemed (CHE) shares did Director George Walsh buy?

He purchased 200 common shares on 08/04/2025.

At what price were the CHE shares acquired?

The shares were bought at $417.10 each.

What is George Walsh’s total direct ownership after the transaction?

His direct holdings increased to 3,523 CHE shares.

Did the filing report any share sales or derivative transactions?

No. The Form 4 lists only the 200-share purchase; no sales or derivative activities were disclosed.

Is the insider purchase considered significant for Chemed investors?

While positive for sentiment, the $83 k buy is small versus Chemed’s market capitalization and is not financially material.